Public Market Listing
Live quotes, historical charts, and market capitalization for Almirall are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
Aclidinium bromide/formoterol fumarate(Duaklir Pressair) | Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary Disease |
lebrikizumab(Ebglyss) | Approved | IL-13Monoclonal antibody | Atopic Dermatitis |
tildrakizumab(Ilumya) | Approved | IL-23 p19Monoclonal antibody | Psoriatic ArthritisPsoriasis |
| US approval withdrawn | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Phase 3 | Nrf2 pathway (fumaric acid ester)Small molecule | Psoriasis |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $703M | — | $405M | — | report ↗ |